Huahai Pharmaceutical announces new sponsor representative for ongoing offerings

Zhejiang Huahai Pharmaceutical Co., Ltd. recently announced a change in its sponsor representative. The company received a letter from its sponsor institution, Zheshang Securities Co., Ltd., stating that Luo Jun, one of the sponsor representatives for the company's public offering of convertible corporate bonds and private placement of shares, will no longer serve in this role due to work requirements.

To ensure the orderly continuation of ongoing supervision, Zheshang Securities has appointed Wang Yiming to take over from Luo Jun as the sponsor representative. Following this change, the sponsor representatives for the company's public offering of convertible corporate bonds and private placement of shares will be Wang Yiming and Pan Xun.

The company emphasizes that this change will not affect Zheshang Securities' sponsorship work for Huahai Pharmaceutical, nor will it impact the company's production and operational activities. Wang Yiming's resume, attached to the announcement, highlights her extensive experience in investment banking since 2007, holding qualifications as a securities practitioner and sponsor representative. Her experience includes involvement in various IPOs, public offerings, and convertible bond projects for multiple companies. The announcement was made by the board of directors of Zhejiang Huahai Pharmaceutical Co., Ltd. on September 23, 2025.